Financings

Accelmed LP is establishing the Accelmed Ventures II fund with a target of approximately $100 million to invest in Israeli and global pre-revenue health tech startups, including medical devices and digital health innovations.

Aprea Therapeutics Inc. said its IPO raised $97.75 million in gross proceeds.

Biontech SE priced its IPO of 10 million American depository shares at $15 each, grossing the company $150 million.

Cygnal Therapeutics Inc. has raised $65 million from Flagship Pioneering.

Heron Therapeutics Inc. is selling about 8.6 million shares at $17.50 each in a public offering, grossing the company approximately $150 million.

Innovent Biologics Inc. raised HK$2.35 billion (US$300 million) by selling 97 million shares at HK$24.60 each.

Mirobio Ltd. has spun out of Oxford University, raising £27 million (US$33.3 million) to develop antibody-based therapies designed to activate immune checkpoint receptors in the treatment of autoimmune disorders.

Nevakar Inc. said it entered a $17.5 million product financing agreement with an affiliate of H.I.G. Capital Partners LP for the continued development of five differentiated, sterile injectable products.

Ovid Therapeutics Inc. is selling 9 million shares at $2.50 each and 4,000 shares of its nonvoting series A convertible preferred stock, grossing the company $32.5 million.

Sorrento Therapeutics Inc. closed its registered direct offering with net proceeds expected to be about $23.3 million.

Upin & Co. Ltd. plans to invest a total of KRW2 trillion (US$1.7 billion) over three years in the South Korean biopharma industry.

Viela Bio Inc. closed its IPO for gross proceeds of approximately $172.6 million.

Deals

4D pharma plc, which is developing Live Biotherapeutics, entered a research collaboration and option to license agreement with Merck & Co. Inc. to discover and develop Live Biotherapeutics for vaccines.

Akcea Therapeutics Inc., a majority owned affiliate of Ionis Pharmaceuticals Inc., and Pfizer Inc. signed an exclusive, worldwide licensing deal for AKCEA-ANGPTL-3-LRx, which is being developed to treat cardiovascular and metabolic diseases.

Alexion Pharmaceuticals Inc. and Stealth Biotherapeutics Corp. reached a deal for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Stealth receives an initial $30 million for an equity investment, option fee and development funding, along with the possibility of additional option-related and milestone-dependent payments if the option is exercised.

BASF SE and Biomillenia SA said they inked a microbiome discovery agreement to identify dermocosmetic active ingredients involved in promoting skin health.

Bluebird Bio Inc. and Novo Nordisk A/S plan to develop in vivo genome editing treatments for genetic diseases, including hemophilia, over the next three years.

Context Therapeutics LLC and the Wisconsin Oncology Network will collaborate on a phase II trial to evaluate complete hormone blockade in treating breast cancer in patients who are resistant to antiestrogen plus CDK4/6 inhibitor therapy.

Glaxosmithkline plc disclosed a five-year collaboration with Lyell Immunopharma Inc. to develop new technologies to improve cell therapies for cancer patients.

Innovate Biopharmaceuticals Inc. and RDD Pharma Ltd. said they plan to merge, with Innovate set to acquire the outstanding capital stock of privately held RDD in exchange for a combination of common and preferred shares.

Insilico Medicine entered a two-program artificial intelligence drug discovery collaboration with Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. focused on previously undruggable targets, beginning with an AI-enabled platform for triple-negative breast cancer.

Parexel International and Datavant said they have established a multiyear strategic partnership to enable the connection of real-world data across all clinical trials conducted by Parexel.

Prometheus Biosciences Inc. signed a deal with Takeda Pharmaceutical Co. Ltd., which brings an undisclosed up-front payment and as much as $420 million more if development, regulatory and commercial milestones are reached in three programs in inflammatory bowel disease.

Ra Pharmaceuticals Inc.'s shares doubled last week as UCB SA made a $48-per-share bid that values the company at about $2.5 billion, or about $2.1 billion net of Ra's cash.

Reata Pharmaceuticals Inc. has agreed to pay former partner Abbvie Inc. $330 million plus royalties to reacquire ex-U.S. development, manufacturing and commercialization rights for the Nrf2 activators bardoxolone methyl and omaveloxolone, as well as other next-generation candidates in the class.

Viela Bio Inc. signed a deal with Mitsubishi Tanabe Pharma Corp. to develop and commercialize Viela's humanized anti-CD19 monoclonal antibody, inebilizumab, in nine Asia regions for the rare disease neuromyelitis optica spectrum disorder as well as other potential future indications.

... And more

A new report by the Institute for Clinical and Economic Review (ICER) reviewed "substantial price increases" in 2017 and 2018 for drugs that already resulted in high current spending. ICER said it found no "new important evidence" to support the increases for seven of the nine drugs studied.

Arbutus Biopharma Corp. discontinued clinical development of AB-506, an oral capsid inhibitor, which is in a clinical trial for treating chronic hepatitis B. The decision was made when two healthy volunteers were found to have acute hepatitis.

Chong Kun Dang Pharmaceutical Corp. received approval for its erythropoiesis-stimulating protein biosimilar from Japan's Ministry of Health, Labour and Welfare.

Clinuvel Pharmaceuticals Ltd.'s Scenesse (afamelanotide) received FDA approval to increase pain-free light exposure in adults with a history of skin damage from the rare inherited disorder erythropoietic protoporphyria.

Gilead Sciences Inc.'s Descovy (emtricitabine and tenofovir alafenamide) received FDA approval for HIV-1 pre-exposure prophylaxis, or PrEP, to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex.

Johnson & Johnson has committed more than $500 million to research and development and delivery programs for HIV and tuberculosis over the next four years to help accelerate the goal of eliminating both diseases by 2030.

Novartis AG gained FDA approval for VEGF-A inhibitor Beovu (brolucizumab) in wet age-related macular degeneration.

The Biotechnology Innovation Organization said president and CEO Jim Greenwood intends to step down after the 2020 election and will help transition a new leader.

The U.K. government has placed an immediate ban on the export of certain drugs in a bid to prevent wholesalers taking advantage of the fall in the value of the pound against the euro by selling off U.K. stockpiles that have been built up to protect against an interruption in supplies in event of a no-deal Brexit.

William Kaelin, Peter Ratcliffe and Gregg Semenza have jointly won the 2019 Nobel Prize "for their discoveries of how cells sense oxygen."

No Comments